Medical Weight Loss Cost UK: The Complete 2026 Pricing Guide

The three ways to access weight loss medication in the UK

There are three routes to accessing prescribed weight loss medication in the UK: NHS prescription, private pay-as-you-go, and private annual membership. Each suits different circumstances, budgets, and timelines.

NHS prescription is the cheapest route, costing £9.90 per item in England (free in Scotland, Wales, and Northern Ireland). A Prescription Prepayment Certificate reduces this further to £111.60 per year for unlimited items. The challenge is access. NHS Mounjaro (tirzepatide) eligibility currently requires a BMI of 40 or above (37.5 for some ethnic groups) plus four qualifying comorbidities, and even then, GP participation is optional under the 2026/27 QOF contract. NHS Wegovy (semaglutide) is available through specialist weight management services, but waiting lists of 6–12 months are common in many areas. For most adults with a BMI of 30–39, the NHS route is not currently realistic.

Private pay-as-you-go gives immediate access to both Wegovy and Mounjaro via an online clinical assessment and prescriber review. You pay per order, typically monthly. Prices vary significantly between providers and change frequently. The market range tables later in this guide give current figures. The key question to ask any provider is: what does the headline price actually include? Some providers charge separately for clinical consultation (£30–£75), prescribing fees (£15–£30), needles, and delivery. Others include everything in a single monthly price.

Private annual membership is a newer model designed for patients who know they'll be on treatment for 12 months or longer. Foundry's Forge membership, for example, charges a £249 annual fee that covers all clinical consultation and prescribing fees for the year. Members then pay only the medication cost per order, with no per-order service fee. This saves over 25% on service fees compared to monthly pay-as-you-go ordering. The membership applies across both Wegovy and Mounjaro, so switching medicines mid-year is covered.

Mounjaro cost UK: all doses (2026)

Mounjaro (tirzepatide) pricing varies widely between UK private providers. The table below shows the current market range alongside Foundry's pay-as-you-go pricing, which includes clinical assessment, prescribing, needles, and sharps bin in every order. Shipping is charged separately at checkout.

The wide variation in Mounjaro pricing across the UK market is largely a consequence of Eli Lilly's September 2025 wholesale price increase, which brought UK list prices closer to other European markets. Lilly simultaneously introduced a rebate programme that pharmacies can opt into. Providers signed up to the rebate can offer lower headline prices than those that are not, which is the primary reason you'll see a £100+ gap between the cheapest and most expensive providers at the same dose.

Foundry's prices include clinical assessment, prescribing by a UK-registered prescriber, needles, and a sharps bin. There is no separate consultation fee or prescribing charge added at checkout. The price shown is the price you pay for the medication and clinical service, with shipping charged separately based on the delivery option selected.

Wegovy cost UK: all doses (2026)

Wegovy (semaglutide) is generally £50–£100 per month cheaper than Mounjaro at comparable dose stages, a shift that became more pronounced after the September 2025 Lilly price increase. The table below shows current market ranges alongside Foundry's pay-as-you-go pricing.

Wegovy's lower cost at equivalent dose stages is a clinically relevant consideration for patients managing a long-term treatment budget. Both drugs are effective for weight management, but if cost is a significant factor, Wegovy offers a more affordable entry point and titration pathway. Your prescriber can advise on which treatment is most appropriate for your clinical profile.

The hidden extras problem: what the headline price often excludes

The most misleading aspect of weight loss medication pricing in the UK is what gets left out of the headline figure. Understanding the true cost means checking what is and is not included before you commit to a provider.

Clinical consultation fees are charged separately by some providers, typically £30–£75 per consultation. This covers the clinical assessment and prescriber review. Some providers charge this once at the start; others charge it with every order or at regular intervals.

Prescribing fees are an additional per-order charge at some pay-as-you-go providers, typically £15–£30. This is separate from the consultation fee and covers the cost of a prescriber issuing each prescription.

Needles and sharps bins are sometimes charged as extras, typically £5–£15 per month. Both are essential for safe injection and disposal. A provider that excludes them from the headline price is deferring a necessary cost.

Cold-chain delivery is required for both Wegovy and Mounjaro, as the medications must be kept refrigerated. Delivery charges range from £5–£15 per order depending on the provider and service level. Even providers who include other extras often charge separately for shipping.

At Foundry, the monthly price shown includes clinical assessment, prescribing, needles, and a sharps bin. There is no separate consultation or prescribing charge added to your order. Shipping is the only additional cost, charged at checkout based on the tracked cold-chain delivery service selected.

What does a full 12-month programme actually cost?

Weight loss medication is not a short-term prescription. Both Wegovy and Mounjaro are designed for sustained use, and most patients remain on treatment for 12 months or longer. Budgeting annually gives a more accurate picture of total cost than looking at the monthly figure alone, particularly because doses typically increase during the first few months of treatment as you titrate upward.

Prices based on starter dose. Individual costs vary by dose reached and titration speed. Foundry prices include clinical assessment, prescribing, needles, and sharps bin. Shipping is charged separately. All figures correct as of April 2026.

Is medical weight loss worth the cost?

The clinical evidence for GLP-1 and dual GLP-1/GIP weight management medications is strong. In the SURMOUNT-1 trial, participants on tirzepatide 15mg (Mounjaro) lost an average of 22.5% of their body weight over 72 weeks. In the STEP UP trial, participants on semaglutide 7.2mg (Wegovy) lost an average of 20.7% over the same period. These are results previously only achievable through bariatric surgery.

The broader economic case is equally clear. A 2023 analysis by the Tony Blair Institute and Frontier Economics estimated the total annual cost of obesity and overweight to the UK economy at £98 billion, including £19 billion in NHS treatment costs and significant productivity losses. For individuals, untreated obesity carries long-term costs through higher rates of type 2 diabetes, cardiovascular disease, joint problems, and associated medication.

There is also a direct household offset that many patients don't initially consider. GLP-1 medications work partly by reducing appetite, and most patients report a significant reduction in food intake during treatment. Depending on your current spending, this can translate to £100–£150 per month in reduced food and drink costs, partially offsetting the cost of medication.

For patients planning to stay on treatment for 12 months or longer, the membership model offers a further saving. Foundry's Forge membership saves over 25% on service fees compared to monthly pay-as-you-go ordering (£249 per year versus £348 in individual service fees over 12 monthly orders). The saving is £99 per year regardless of dose or drug.

How to keep costs down without compromising safety

1. Check NHS eligibility first. Before committing to private treatment, confirm whether you qualify for NHS access. If your BMI is 40 or above with qualifying comorbidities, you may be eligible for NHS Mounjaro through your GP (if your practice participates in the QOF programme). NHS Wegovy is available through specialist weight management services. Even with waiting times, it's worth checking.

2. Compare total cost, not headline price. A provider advertising Mounjaro at £124 per month may charge £30 for consultation and £10 for needles on top. That's £164, not £124. Before choosing a provider, ask: does the price include clinical assessment, prescribing, needles, and sharps? What does delivery cost? Get the total figure and compare like for like.

3. Consider an annual membership if you're staying on treatment. If you plan to use medication for 12 months or longer, an annual membership model like Foundry's Forge (£249 per year) eliminates per-order service fees. The saving over 12 months is £99 compared to monthly pay-as-you-go, and the membership covers switching between Mounjaro and Wegovy if your prescriber recommends it.

4. Start with Wegovy if cost is a primary concern. Wegovy is currently £50–£100 per month cheaper than Mounjaro at comparable dose stages. Both are clinically effective for weight management. If cost is a significant factor in your decision, discuss the Wegovy pathway with your prescriber.

5. Use a UK-regulated provider. This is a safety point, not a cost point, but it protects you financially too. Unregulated sellers offering steep discounts may be supplying counterfeit, diverted, or incorrectly stored medication. If the medication doesn't work or causes harm, the initial saving becomes irrelevant. Check that your provider's pharmacy is GPhC-registered and that prescribing is handled by GMC-registered prescribers.

6. Factor in reduced food spending. Most patients on GLP-1 medication report lower appetite and reduced food intake. Track your food and drink spending for the first two months of treatment. Many patients find that £100–£150 per month in reduced grocery and dining costs partially offsets the cost of medication.

7. Don't pay for a higher dose than you need. Dose escalation follows a clinical titration schedule. Your prescriber will increase your dose only when clinically appropriate. If you're achieving good results at a lower dose, there's no clinical reason to escalate faster, and staying at a lower dose for longer reduces your monthly cost.

Frequently asked questions